ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Low-Dose eye radiation shows promise for lymphoma control
Disease control OngoingThis study tests whether a very low dose of radiation (4 Gy) can effectively control indolent B-cell lymphoma or mantle cell lymphoma that has spread to the eye socket. About 50 adults with stage I-IV disease will receive this targeted treatment. The goal is to shrink or stop the…
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
Immunotherapy-Chemo combo shows promise for tough lymphoma
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease will receive the combination, followed by a short cours…
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
New drug duo shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…
Matched conditions: ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 20, 2026 11:55 UTC